Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Daily Top 10 COVID-19 papers DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM

Leukemia

Free Subscription 30.03.2020 1 Am J Clin Pathol 7 Am J Hematol 3 Ann Hematol 3 Blood 5 Bone Marrow Transplant 8 Br J Haematol 1 Cancer Chemother Pharmacol 1 Cancer Lett 1 Genes Chromosomes Cancer 2 Int J Hematol 1 J Biol Chem 2 J Pediatr Hematol Oncol 3 Leuk Lymphoma 1 Leuk Res 6 Leukemia 2 Oncogene 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Pathol

1. WEINBERG OK, Kuo F, Calvo KR
   Germline Predisposition to Hematolymphoid Neoplasia.
   Am J Clin Pathol. 2019;152:258-276.
   PubMed         Abstract available
   
   

   
   Am J Hematol

2. HAN X, Wang C, Zhou J
   Chimeric antigen receptor T (CAR-T) cells present with reactive and pleomorphic morphology in bone marrow.
   Am J Hematol. 2019;94:1297-1298.
   PubMed        
   
   
3. PENTHER D, Etancelin P, Lusina D, Bidet A, et al
   Isolated isochromosomes i(X)(p10) and idic(X)(q13) are associated with myeloid malignancies and dysplastic features.
   Am J Hematol. 2019;94:E285-E288.
   PubMed        
   
   
4. AMBINDER AJ, Hambley B, Shanbhag S, Merrill SA, et al
   Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
   Am J Hematol. 2019;94:E296-E299.
   PubMed        
   
   
5. NISHIWAKI S, Mizuta S, Ohashi K, Fukuda T, et al
   Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph + ALL with minimal residual disease.
   Am J Hematol. 2019;94:E301-E305.
   PubMed        
   
   
6. MOLICA M, Breccia M, Foa R, Jabbour E, et al
   Maintenance therapy in AML: The past, the present and the future.
   Am J Hematol. 2019;94:1254-1265.
   PubMed         Abstract available
   
   
7. KOWALCZYK JR, Zawitkowska J, Lejman M, Drabko K, et al
   Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial.
   Am J Hematol. 2019;94:E307-E310.
   PubMed        
   
   
8. MERLI M, Passamonti F
   A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!
   Am J Hematol. 2019;94:1303-1305.
   PubMed        
   
   

   
   Ann Hematol

9. VAN DER STRATEN L, Kater AP, Doorduijn JK, van den Broek EC, et al
   Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia.
   Ann Hematol. 2020 Mar 19. pii: 10.1007/s00277-020-03994.
   PubMed         Abstract available
   
   
10. PERINGETH G, Sundaram S, Bogner P, Conroy E, et al
    Successful use of venetoclax for treatment of eosinophilic dermatosis of myeloproliferative disease in a patient with chronic lymphocytic leukemia.
    Ann Hematol. 2020 Mar 19. pii: 10.1007/s00277-020-03991.
    PubMed        
    
    
11. ERNST P, Engmann B, Frietsch JJ, Schnetzke U, et al
    A 19-year-old patient with atypical chronic myeloid leukemia.
    Ann Hematol. 2020 Mar 19. pii: 10.1007/s00277-020-03992.
    PubMed        
    
    

    
    Blood

12. BORROW J, Dyer SA, Akiki S, Griffiths MJ, et al
    Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT.
    Blood. 2019;134:2291-2303.
    PubMed         Abstract available
    
    
13. TRAER E
    Reducing acetyl-CoA enhances BET inhibition.
    Blood. 2019;134:2122-2123.
    PubMed        
    
    
14. VASSILIOU GS
    The curious incident of TdT-mediated mutations in AML.
    Blood. 2019;134:2229-2231.
    PubMed        
    
    

    
    Bone Marrow Transplant

15. YAMASHITA T, Takami A, Uchida N, Fukuda T, et al
    Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
    Bone Marrow Transplant. 2020 Mar 12. pii: 10.1038/s41409-020-0856.
    PubMed         Abstract available
    
    
16. TERAKURA S, Nishida T, Sawa M, Kato T, et al
    Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2020 Mar 16. pii: 10.1038/s41409-020-0859.
    PubMed         Abstract available
    
    
17. BRISSOT E, Labopin M, Russo D, Martin S, et al
    Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2020 Mar 17. pii: 10.1038/s41409-020-0849.
    PubMed         Abstract available
    
    
18. ROVIRA M, Villamor N, Cobo F, Fernandez-Aviles F, et al
    Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation.
    Bone Marrow Transplant. 2020 Mar 20. pii: 10.1038/s41409-020-0861.
    PubMed        
    
    
19. YANADA M, Fukuda T, Tanaka M, Ota S, et al
    Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data.
    Bone Marrow Transplant. 2020 Mar 20. pii: 10.1038/s41409-020-0868.
    PubMed         Abstract available
    
    

    
    Br J Haematol

20. MALIK B, Taylor GP
    Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15234.
    PubMed        
    
    
21. AGRAWAL AK, Aguilar A, Feusner J
    Unifying the diagnosis of isolated central nervous system relapse in acute lymphoblastic leukaemia based on minimal residual disease testing.
    Br J Haematol. 2019;184:1026-1027.
    PubMed        
    
    
22. BOMBEN R, Roisman A, D'Agaro T, Castellano G, et al
    Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.2-202 has prognostic value in Chronic Lymphocytic Leukaemia.
    Br J Haematol. 2019;184:1045-1050.
    PubMed        
    
    
23. BERGER G, van den Berg E, Smetsers S, Leegte BK, et al
    Fanconi anaemia presenting as acute myeloid leukaemia and myelodysplastic syndrome in adulthood: a family report on co-occurring FANCC and CHEK2 mutations.
    Br J Haematol. 2019;184:1071-1073.
    PubMed        
    
    
24. PIREDDA ML, Gaur G, Catalano G, Divona M, et al
    PML/RARA inhibits expression of HSP90 and its target AKT.
    Br J Haematol. 2019;184:937-948.
    PubMed         Abstract available
    
    
25. IMPROGO MR, Tesar B, Klitgaard JL, Magori-Cohen R, et al
    MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.
    Br J Haematol. 2019;184:925-936.
    PubMed         Abstract available
    
    
26. BARZILAI-BIRENBOIM S, Arad-Cohen N, Nirel R, Avrahami G, et al
    Thrombophilia screening and thromboprophylaxis may benefit specific ethnic subgroups with paediatric acute lymphoblastic leukaemia.
    Br J Haematol. 2019;184:994-998.
    PubMed         Abstract available
    
    
27. IFVERSEN M, Turkiewicz D, Marquart HV, Winiarski J, et al
    Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.
    Br J Haematol. 2019;184:982-993.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

28. LIN TL, Newell LF, Stuart RK, Michaelis LC, et al
    A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
    Cancer Chemother Pharmacol. 2019;84:163-173.
    PubMed         Abstract available
    
    

    
    Cancer Lett

29. AKIYAMA H, Umezawa Y, Ishida S, Okada K, et al
    Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.
    Cancer Lett. 2019;453:84-94.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

30. BLACKBURN PR, Smadbeck JB, Znoyko I, Webley MR, et al
    Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia.
    Genes Chromosomes Cancer. 2020 Mar 20. doi: 10.1002/gcc.22842.
    PubMed         Abstract available
    
    

    
    Int J Hematol

31. KIYOI H, Yamaguchi H, Maeda Y, Yamauchi T, et al
    JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML).
    Int J Hematol. 2020 Mar 23. pii: 10.1007/s12185-020-02856.
    PubMed        
    
    
32. URESHINO H, Kamachi K, Kimura S
    Does patient sex play a role in treatment-free remission in chronic myeloid leukemia?
    Int J Hematol. 2020 Mar 21. pii: 10.1007/s12185-020-02864.
    PubMed        
    
    

    
    J Biol Chem

33. DUVAL R, Bui LC, Mathieu C, Nian Q, et al
    Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
    J Biol Chem. 2019;294:12483-12494.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

34. EL-KHOURY H, Chahrour M, Ghanem KM, Saifi O, et al
    Isolated Central Nervous System Relapse Following Treatment Reduction in Low-risk Acute Lymphoblastic Leukemia at the Children's Cancer Center of Lebanon.
    J Pediatr Hematol Oncol. 2020 Mar 20. doi: 10.1097/MPH.0000000000001785.
    PubMed         Abstract available
    
    
35. SABULSKI A, Bartlett AL, Koch BL, Vatner R, et al
    Hyperdiploid Precursor B-acute Lymphoblastic Leukemia Presenting as a Cavernous Sinus Mass in a 4-Year-old Male.
    J Pediatr Hematol Oncol. 2020 Mar 20. doi: 10.1097/MPH.0000000000001783.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

36. TANEJA A, Jones J, Pittaluga S, Maric I, et al
    Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
    Leuk Lymphoma. 2018 Jul 6:1-4. doi: 10.1080/10428194.2018.1480775.
    PubMed        
    
    
37. DELSING MALMBERG E, Johansson Alm S, Nicklasson M, Lazarevic V, et al
    Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.
    Leuk Lymphoma. 2018 Aug 2:1-9. doi: 10.1080/10428194.2018.1485910.
    PubMed         Abstract available
    
    
38. MCCARTER SJ, Vijayvargiya P, Sidana S, Nault AM, et al
    A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses.
    Leuk Lymphoma. 2019;60:559-561.
    PubMed        
    
    

    
    Leuk Res

39. OZGUR YURTTAS N, Eskazan AE
    Novel therapeutic approaches in chronic myeloid leukemia.
    Leuk Res. 2020;91:106337.
    PubMed         Abstract available
    
    

    
    Leukemia

40. ESKAZAN AE
    Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?
    Leukemia. 2020 Mar 13. pii: 10.1038/s41375-020-0796.
    PubMed        
    
    
41. BLAESCHKE F, Willier S, Stenger D, Lepenies M, et al
    Leukemia-induced dysfunctional TIM-3(+)CD4(+) bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients.
    Leukemia. 2020 Mar 13. pii: 10.1038/s41375-020-0793.
    PubMed         Abstract available
    
    
42. MONTESINOS P, Roboz GJ, Bulabois CE, Subklewe M, et al
    Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
    Leukemia. 2020 Mar 16. pii: 10.1038/s41375-020-0773.
    PubMed         Abstract available
    
    
43. BEST S, Lam V, Liu T, Bruss N, et al
    Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
    Leukemia. 2020 Mar 16. pii: 10.1038/s41375-020-0794.
    PubMed         Abstract available
    
    
44. AL-SAWAF O, Robrecht S, Bahlo J, Fink AM, et al
    Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.
    Leukemia. 2020 Mar 17. pii: 10.1038/s41375-020-0797.
    PubMed         Abstract available
    
    
45. FOUSEK K, Watanabe J, Joseph SK, George A, et al
    CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
    Leukemia. 2020 Mar 24. pii: 10.1038/s41375-020-0792.
    PubMed         Abstract available
    
    

    
    Oncogene

46. FLOREN M, Restrepo Cruz S, Termini CM, Marjon KD, et al
    Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and beta1 integrin activation.
    Oncogene. 2020 Mar 19. pii: 10.1038/s41388-020-1261.
    PubMed         Abstract available
    
    
47. SHIBATA N, Ohoka N, Tsuji G, Demizu Y, et al
    Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells.
    Oncogene. 2020 Mar 12. pii: 10.1038/s41388-020-1253.
    PubMed         Abstract available
    
    

    
    PLoS One

48. COLLIVA C, Cellini M, Dalla Porta F, Ferrari M, et al
    Psychosocial assessment of families caring for a child with acute lymphoblastic leukemia, epilepsy or asthma: Psychosocial risk as network of interacting symptoms.
    PLoS One. 2020;15:e0230194.
    PubMed         Abstract available
    
    
49. PATEL RK, Weir MC, Shen K, Snyder D, et al
    Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
    PLoS One. 2019;14:e0225887.
    PubMed         Abstract available
    
    
50. WUNDERLICH M, Manning N, Sexton C, Sabulski A, et al
    Improved chemotherapy modeling with RAG-based immune deficient mice.
    PLoS One. 2019;14:e0225532.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: